Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
The robotic surgery giant is finally being challenged by companies even bigger than itself.
The agency takes its time – particularly with diagnostics.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.